2025 Dividend Kings: Strong Run Continues
The Dividend Kings are outperforming the S&P 500 in 2025 by 4.57%. Top performers include National Fuel & Gas (+30.21%), Consolidated Edison (+22.66%), and AbbVie (+20.40%). Promising Dividend Kings identified in February showed relative outperformance, averaging -0.38% vs. -1.58% for all Kings and -3.34% for SPY.
seekingalpha.com
Read More
Kenvue Ribbon-Cutting Marks Official Opening of New Global Headquarters in Summit, New Jersey
SUMMIT, N.J.--(BUSINESS WIRE)--Today, Kenvue Inc. (NYSE: KVUE) held a ribbon-cutting ceremony for its new 290,000 sq. ft. global headquarters in Summit, New Jersey.
businesswire.com
Read More
Kenvue + Johnson & Johnson: I Choose To Own The Whole 'Humpty Dumpty'
Johnson & Johnson's spin-off of Kenvue has created two resilient defensive stocks in the healthcare sector, ideal for accumulation during market volatility. Despite being off their highs, both JNJ and Kenvue present attractive buying opportunities due to their low betas and relatively high dividends. These are exactly the resilient defensive stocks in an un-loved healthcare sector that investors are now piling into as the VIX spikes.
seekingalpha.com
Read More
Buy 2 March S&P 500 Dividend Aristocrats Out Of 37 'Safer'
Four of the ten lowest-priced Dividend Aristocrats, including Franklin Resources and Realty Income, are ready to buy with annual dividends exceeding their single share prices. Analysts forecast 15.93% to 26.49% net gains for top-ten Aristocrat Dogs by March 2026, with Federal Realty and Stanley Black & Decker leading. A market correction of 65% could make all top-yield Aristocrats fair-priced, with dividends from $1K invested meeting or exceeding their single share prices.
seekingalpha.com
Read More
Recession Could Be Coming: 5 Strong Buy High-Yield Dividend Stocks That Will Still Outperform
The last time the economy experienced two negative quarters of gross domestic product was the first and second quarters of 2022, with a 1.6% pullback in the first quarter and a 0.6% decline in the second.
247wallst.com
Read More
Kenvue to Showcase New Clinical Data on Skin Longevity, Hydration and Sun Protection at American Academy of Dermatology Association Meeting
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will share new clinical data demonstrating how its iconic brands are leveraging the latest science to shape the future of the Skin Health & Beauty category at the 2025 American Academy of Dermatology (AAD) Annual Meeting, set for March 7-11, 2025 at the Orlando Convention Center in Orlando, Florida. In findings from the 14 clinical studies detailing new Kenvue scientific research, the Company will present evidence alongside industry.
businesswire.com
Read More
Faber Report: Kenvue settles proxy fight with activist Starboard
CNBC's David Faber breaks down the latest news on Kenvue.
youtube.com
Read More
Kenvue settles proxy fight with activist Starboard, appoints three directors
Consumer health company Kenvue said on Wednesday it had appointed three new directors to its board as part of an agreement with activist investor Starboard Value.
reuters.com
Read More
Kenvue settles proxy fight with activist Starboard
CNBC's David Faber joins 'Squawk Box' to report on the latest news.
youtube.com
Read More
Kenvue settles proxy fight with activist Starboard, sources tell CNBC
Kenvue settles proxy fight with activist Starboard, sources tell CNBC
cnbc.com
Read More
3 Great Value Stocks That Could Crush the S&P 500 This Year
With the overall market looking expensive, it can be prudent for investors in search of new stocks to add to their portfolios to dig into companies that, for whatever reason, are trading at discounts. Some might have the potential to close their valuation gaps and become above-average investments.
fool.com
Read More
3 Top High-Yield Dividend Stocks I Just Bought in My Retirement Account
I'm filling my retirement account with dividend stocks. While I like to see the passive income flow into my portfolio, that's not the main factor.
fool.com
Read More
Buy 3 "Safer" Dividend Kings Of 24 Out Of 52 For February
Seven of the top-ten Dividend Kings by yield offer annual dividends from a $1K investment exceeding their single share prices, making them attractive buys. Six Dividend Kings, including Altria Group and Hormel Foods, are currently fair-priced, with dividends meeting or exceeding their single-share prices. Analysts predict net gains between 15% and 45.53% for the top-ten Dividend Kings by February 2026, based on target prices.
seekingalpha.com
Read More
Buy This Ultra-Safe High-Yield Dividend King Stock for Reliable Passive Income
Kenvue (KVUE 0.54%) stock is down since completing its spin-off from Johnson & Johnson (JNJ 1.13%) in August 2023. But with more than a year of results now in the books, investors have had time to acclimate to Kenvue as an independent entity.
fool.com
Read More
Looming Challenges, But Kenvue Could Become A Compelling Dividend Growth Stock Beyond 2025
Kenvue, spun off from Johnson & Johnson, shows potential as a solid dividend stock post-2025 despite current economic challenges and recent earnings misses. The company boasts strong brands like Tylenol and Listerine, and management's cost-cutting initiatives aim to save $350 million by 2026. Kenvue's valuation and growth prospects make it attractive for long-term dividend investors, but cash flow headwinds warrant a hold rating for now.
seekingalpha.com
Read More
Buy 2 February S&P 500 Dividend Aristocrats Out Of 38 'Safer'
Five of the ten lowest-priced Dividend Aristocrats - Franklin Resources, Realty Income, Amcor, Hormel, and Kenvue - are recommended buys, offering dividends exceeding their single share prices. Analysts project net gains of 15.84% to 46.98% by February 2025 for the Top Ten Aristocrat Dogs, with an average gain of 21.63%. Ten Aristocrats show negative free cash flow margins, making them unsafe buys; Federal Realty, Kenvue, and PepsiCo are among them.
seekingalpha.com
Read More
Kenvue to Webcast Presentation at the Consumer Analyst Group of New York Conference
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced Thibaut Mongon, Chief Executive Officer, Paul Ruh, Chief Financial Officer, and Charmaine England, Chief Growth Officer, will present at the Consumer Analyst Group of New York (CAGNY) Conference on Wednesday, February 19, 2025, at 3:00 p.m. Eastern Time. A live webcast of the presentation will be available on investors.kenvue.com and a replay will be available on the website following the event. About Kenvue Kenvue Inc. i.
businesswire.com
Read More
Kenvue: An Intriguing Turnaround
Kenvue's stock has underperformed since its IPO, with disappointing guidance cuts for 2023 and 2024, and minimal growth projected for 2025. Despite recent struggles, Kenvue's strong brand portfolio, including Tylenol and Band-Aid, suggests potential for a turnaround, supported by activist investor Starboard Value. Execution issues, external factors, and potential structural changes have impacted Kenvue's performance, but improvements in marketing and management could drive future growth.
seekingalpha.com
Read More
Kenvue Is A Mediocre Candidate
Kenvue, the world's largest pure-play consumer health company, has a market cap of $37.96 billion but struggles with profitability despite decent growth. Management's cost-cutting initiatives show promise, but recent financials reveal mixed results, with revenue slightly up but net income and EBITDA declining. Kenvue's valuation appears relatively cheap compared to peers, yet its fundamentals don't justify a bullish outlook; thus, I rate it a 'hold'.
seekingalpha.com
Read More
Kenvue, Inc. (KVUE) Q4 2024 Earnings Call Transcript
Kenvue, Inc. (NYSE:KVUE ) Q4 2024 Earnings Conference Call February 6, 2025 8:00 AM ET Company Participants Thibaut Mongon - CEO Paul Ruh - CFO Sofya Tsinis - Head, IR Conference Call Participants Filippo Falorni - Citi Peter Grom - UBS Anna Lizzul - Bank of America Andrea Teixeira - J.P. Morgan Bonnie Herzog - Goldman Sachs Korinne Wolfmeyer - Piper Sandler Nik Modi - RBC Capital Markets Lauren Lieberman - Barclays Steve Powers - Deutsche Bank Operator Hello, and welcome to the Kenvue Fourth Quarter and Full-Year 2024 Earnings Conference Call.
seekingalpha.com
Read More
Kenvue (KVUE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Kenvue (KVUE) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zacks.com
Read More
Kenvue's Q4 Sales Miss, Margins Improve
Consumer healthcare products specialist Kenvue (KVUE -0.34%) reported mixed fourth-quarter and full-year earnings on Thursday, Feb. 6. Adjusted earnings per share (EPS) of $0.26 aligned with the market's consensus expectations.
fool.com
Read More
Kenvue (KVUE) Q4 Earnings Meet Estimates
Kenvue (KVUE) came out with quarterly earnings of $0.26 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.31 per share a year ago.
zacks.com
Read More
Kenvue sees 2025 profit below estimates as strong dollar, weak cough product sales hit
Consumer health company Kenvue forecast 2025 adjusted profit below Wall Street estimates on Thursday, hit by a stronger dollar and weak demand for its cough and cold products that include Tylenol and Benadryl.
reuters.com
Read More
Kenvue Reports Full Year and Fourth Quarter 2024 Results
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), today announced financial results for the full year and fiscal fourth quarter ended December 29, 2024. “We delivered on our 2024 profit commitments despite headwinds that resulted in softer than expected sales growth and we enter 2025 as a more competitive company with stronger foundations,” said Thibaut Mongon, Chief Executive Officer. “We remain focused on leveraging our increased brand investments to accelerate growth and deliver lon.
businesswire.com
Read More
Kenvue Highlights Commitment to Shareholder Value
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue confirms receipt of Starboard Value submission of nominees to stand for election to the Kenvue Board of Directors from.
businesswire.com
Read More
Neutrogena® Introduces Tate McRae as Global Brand Ambassador
On the Heels of its 10th Anniversary, the Brand's Iconic Hydro Boost Collection Is Revealing a Juicy, Fresh Take SKILLMAN, N.J. , Feb. 4, 2025 /PRNewswire/ -- Kenvue Inc. (NYSE: KVUE) announces global sensation Tate McRae as the newest face of Neutrogena®.
prnewswire.com
Read More
All It Takes Is $3,000 Invested in Each of These 3 Ultra-Reliable Dividend King Stocks to Help Generate Over $300 in Passive Income in 2025
Dividends can be a great way to generate income from stocks, no matter what the market is doing. But only if the companies paying the dividends are reliable.
fool.com
Read More
Gear Up for Kenvue (KVUE) Q4 Earnings: Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Kenvue (KVUE) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
zacks.com
Read More
Kenvue (KVUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Kenvue (KVUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
Read More
4 Consumer Staple Stocks Likely to Top Earnings Estimates This Season
Companies with solid brands and efficient cost-management efforts are poised to shine amid a dynamic consumer landscape. KMB, CHD, CLX and KVUE are in focus.
zacks.com
Read More
Kenvue to Announce Fourth Quarter and Full Year 2024 Results on February 6, 2025
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce its fourth quarter and full year 2024 financial results before market open on February 6, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a repla.
businesswire.com
Read More
These Dividend Stocks Fell Between 1% and 20% in 2024. Here's Why They Are Too Cheap to Ignore and Worth Buying in 2025.
2024 was a phenomenal year for broader indexes like the S&P 500 and Nasdaq Composite. But not all stocks joined the party.
fool.com
Read More
JPMorgan Analyst Focus List Includes 5 of Our Favorite High-Yield Dividend Giants
Investors love dividend stocks, especially the high-yield variety, because they offer a significant income stream and have massive total return potential.
247wallst.com
Read More
4 High-Yield Dividend Kings Baby Boomers Count on for Safe Passive Income
With the youngest baby boomers (Americans born between 1946 and 1964) approaching retirement age, it's becoming increasingly important to focus on magnificent dividend stocks that will supply significant passive income either in or out of designated retirement accounts like IRAs.
247wallst.com
Read More
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
Being a long-term investor brings a unique peace of mind. It requires thinking in decades, not months or years, which allows an investor to focus on owning exceptional businesses.
fool.com
Read More
Kenvue Declares Quarterly Cash Dividend
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors has declared a quarterly dividend of $0.205 per share on Kenvue's common stock. This quarterly dividend is payable on February 26, 2025, to shareholders of record as of the close of business on February 12, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID®.
businesswire.com
Read More
Buy 3 'Safer' Dividend Kings Of 25 From 53 For January
“A Dividend King [is] a stock with 50 or more consecutive years of dividend increases.”—suredividend.com. 53 Divided Kings, screened as of January 10, 2025, represented all eleven Morningstar Sectors. Broker-estimated top-ten net-gains ranged 22.84%-62.53% topped-by SJW & SCL. By yield, MO topped all the Kings. Top-ten Yields from KVUE, SWK, UBSI, FTS, FRT, BKH, NWN, CDUAF, UVV, & MO, averaged 5.04%.
seekingalpha.com
Read More
Will Kenvue (KVUE) Beat Estimates Again in Its Next Earnings Report?
Kenvue (KVUE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
zacks.com
Read More
Buy 1 January S&P 500 Dividend Aristocrat Out Of 38 'Safer'
**Investment Thesis:** January's top-yielding Aristocrats include Franklin Resources, Realty Income, Amcor, Kenvue, and Hormel, offering dividends from $1K investments exceeding single share prices. **Rating Justification:** Six more Aristocrats could meet the ideal dividend-to-price ratio with a 45.4% market downturn, making them fair-priced investment opportunities. **Analyst Projections:** Top-ten Aristocrats are expected to deliver 22% to 33.36% net gains by January 2025, with an average net gain of 24.96%.
seekingalpha.com
Read More
Jefferies Top 2025 Stock Picks Include 5 Sizzling Large Cap Dividend Blue Chips
As the calendar turns over to 2025, the leading Wall Street firms are releasing their top stock picks for the new year.
247wallst.com
Read More
3 Dividend-Paying Value Stocks to Buy Even If There's a Stock Market Sell-Off in 2025
Investors worried about a stock market sell-off may feel the urge to sell out of their positions and run for the exits. But long-term investors know that it's a mistake to overhaul your investing strategy based on emotion.
fool.com
Read More
A Bull Market Is Here: 2 Super Stocks Down 21% and 30% to Buy Right Now
Even with the recent bout of market volatility, 2024 has been a fantastic year for stocks. The S&P 500 index has delivered a dividend-adjusted total return of roughly 25% across this year's trading.
fool.com
Read More
Buy 6 December Dividend Kings But Watch 22 With 'Safer' Dividends
"A Dividend King [is] a stock with 50 or more consecutive years of dividend increases." - suredividend.com. 53 Divided Kings, screened as of December 11, 2024, represented all eleven Morningstar Sectors. Broker-estimated top-ten net gains ranged from 14.79% to 25.23%, topped by SJW and SWK. By yield, MO topped all the Kings. Top-ten yields from ABBV, ADM, SWK, FRT, FTS, BKH, NWN, CDUAF, UVV, and MO averaged 4.67%.
seekingalpha.com
Read More
Buy 1 December Aristocrat Of 67 From 38 With 'Safer' Dividends
"Dividend Aristocrats
seekingalpha.com
Read More
Like Passive Income? Then You'll Love These 3 Super Safe Dividend Stocks That Are Up Between 28% and 42% in 6 Months.
Investors often gravitate toward super safe dividend stocks to collect passive income and limit market volatility. But sometimes, even stodgy, boring companies can crush the market.
fool.com
Read More
Kenvue: Lots Of Potential, But Short-Term Upside May Be Tapped Out (Rating Downgrade)
Kenvue's recent earnings showed improvements, but persistent headwinds, especially in the Skin, Health, & Beauty segment, suggest limited upside potential in the near term. Despite solid dividend growth and cost-cutting initiatives, higher interest rates and economic challenges in China continue to weigh on Kenvue's performance. Management's strategic moves, including increased online presence and partnerships with influencers, aim to combat headwinds and drive future growth.
seekingalpha.com
Read More
Kenvue Announces Participation in the Morgan Stanley Global Consumer & Retail Conference
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) (“Kenvue”) today announced the Company's participation in the Morgan Stanley Global Consumer & Retail Conference in New York City. Thibaut Mongon, Chief Executive Officer and Paul Ruh, Chief Financial Officer will participate in a fireside chat on Wednesday, December 4, 2024, at 11:45 a.m. Eastern Time. A live webcast of the fireside chat will be available on investors.kenvue.com and a replay will be available on the website followin.
businesswire.com
Read More
Tylenol maker Kenvue hails efficiency gains as activist Starboard watches on
Kenvue Inc (NYSE:KVUE), the maker of Listerine, Tylenol, Aveeno and Band-Aid, reported slightly lower sales than expected but earnings were just above Wall Street estimates. The company has been in a more intense spotlight coming into these results after reports emerged that activist investor Starboard Value has taken a stake and is eyeing changes.
proactiveinvestors.com
Read More
Kenvue, Inc. (KVUE) Q3 2024 Earnings Call Transcript
Kenvue, Inc. (NYSE:KVUE ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Sofya Tsinis - Head, IR Thibaut Mongon - CEO Paul Ruh - CFO Conference Call Participants Bonnie Herzog - Goldman Sachs Anna Lizzul - Bank of America Andrea Teixeira - J.P. Morgan Peter Grom - UBS Filippo Falorni - Citi Steve Powers - Deutsche Bank Keith Devas - Jefferies Nik Modi - RBC Capital Markets Korinne Wolfmeyer - Piper Sandler Jeremy Fialko - HSBC Operator Hello, and welcome to the Kenvue Third Quarter 2024 Earnings Conference Call.
seekingalpha.com
Read More
Here's What Key Metrics Tell Us About Kenvue (KVUE) Q3 Earnings
Although the revenue and EPS for Kenvue (KVUE) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zacks.com
Read More
Kenvue (KVUE) Q3 Earnings Surpass Estimates
Kenvue (KVUE) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.31 per share a year ago.
zacks.com
Read More
Kenvue misses quarterly sales estimates on sluggish skincare sales
Kenvue reported third-quarter sales marginally below Wall Street estimates on Thursday, hurt by weakness in its skin health and beauty unit housing the Neutrogena and Aveeno brands, amid pressure from activist hedge fund Starboard Value.
reuters.com
Read More
Kenvue Reports Third Quarter 2024 Results
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) (“Kenvue”), today announced financial results for the fiscal third quarter ended September 29, 2024.
businesswire.com
Read More
Stay Ahead of the Game With Kenvue (KVUE) Q3 Earnings: Wall Street's Insights on Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Kenvue (KVUE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
zacks.com
Read More
This Big New Development Could Be Bullish for Kenvue Stock
Can tinkering around the edges actually make this stock more attractive?
fool.com
Read More
3 Dividend Stocks to Double Up on Right Now
While tech-based growth stocks might seem like the right play, you can't ignore dividends if you want to have a strong portfolio.
fool.com
Read More
Billionaire Ken Griffin Just Increased His Position in This Dividend Stock by 5,848%. Here's Why Now May Be a Great Time to Buy.
Ken Griffin's Citadel just added 18 million shares of an under-the-radar consumer health stock.
fool.com
Read More
Meet the 3.6%-Yielding Dividend King Stock That's Up 25% in 3 Months
An activist investor is taking a stake in Kenvue stock.
fool.com
Read More
How activist Starboard may help boost value in Kenvue's skin and beauty business
Starboard Value and Kenvue seem to be aligned, and the conditions might be right for value creation.
cnbc.com
Read More
Is Kenvue Stock a Buy Now?
The growth rate of the consumer healthcare business could accelerate now that an activist investor is involved.
fool.com
Read More
Starboard Makes Its Case to Shake-Up Pfizer and Kenvue
Starboard has a $1 billion stake in Pfizer and an unknown but "sizable" stake in Kenvue, according to earlier media reports.
barrons.com
Read More
Starboard says Kenvue's skin health segment is weighing on performance
Starboard Value called consumer products company Kenvue a bargain and said its skin health and beauty segment's lackluster growth is the reason for the stock's underperformance.
reuters.com
Read More
3-Stock Lunch: Kenvue, UPS & Disney
Sylvia Jablonski, Defiance ETF co-founder, joins 'Power Lunch' to discuss stock plays for three stocks.
youtube.com
Read More
Investor Hoping To "Band-Aid" KVUE Stock Price
The Wall Street Journal reported that Starboard Value has taken a "sizeable" stake in Kenvue (KVUE) with hopes of matching the company's stock price to competitors. Despite having Tylenol and Band-Aid as part of its brand portfolio, George Tsilis looks at the headwinds facing Kenvue's growth.
youtube.com
Read More
Kenvue gains on reports activist investor Starboard Value has taken ‘sizeable' stake
Kenvue Inc (NYSE:KVUE) shares moved more than 6% higher on reports activist investor Starboard Value has taken a stake in the consumer goods company and is eyeing changes. A person familiar with the matter told the Wall Street Journal that Starboard's stake in the Tylenol-maker is “sizeable.
proactiveinvestors.com
Read More
Starboard Value Buys Into Dow Jones Spinoff; Elf Beauty Rallies
Elf Beauty appeared to rally along with KVUE on Monday.
investors.com
Read More
Tylenol Maker Kenvue Stock Surges on Report Starboard Takes 'Sizable Stake'
Shares of Kenvue (KVUE) took off Monday morning on indications activist investor Starboard Value has taken a large stake in the consumer health products maker.
investopedia.com
Read More
Kenvue shares surge after activist Starboard takes stake
Starboard Value has amassed a significant stake in Kenvue, which spun out of Johnson & Johnson in mid-2023, according to people familiar with the matter. Starboard's Jeff Smith is expected to detail the position further at 13D Monitor's Active-Passive Investor Summit on Tuesday.
cnbc.com
Read More
Starboard Targets Another Health Company. Why Kenvue Is in Its Sights.
Tylenol, Listerine and Band-Aid maker Kenvue has attracted the activist investor, according to a report.
barrons.com
Read More
Starboard reportedly takes big stake in Tylenol maker Kenvue
Activist investor Starboard Value has taken a sizeable stake in Kenvue, the maker of Tylenol and Listerine, and is seeking changes, according to reports Sunday night.
marketwatch.com
Read More
Activist investor Starboard Value takes stake in consumer products maker Kenvue, sources say
Activist investor Starboard Value has a stake in Kenvue , which makes Listerine and Tylenol, two sources familiar with the matter told Reuters on Sunday.
reuters.com
Read More
Activist Starboard Value Takes Stake in Tylenol-Maker Kenvue
Starboard wants Kenvue, which was spun out of Johnson & Johnson last year and has a market value of over $40 billion, to make changes to boost its share price.
wsj.com
Read More
Kenvue to Announce Third Quarter 2024 Results on November 7, 2024
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) (“Kenvue”) will announce its third quarter 2024 financial results before market open on November 7, 2024.
businesswire.com
Read More
Analysts Estimate Kenvue (KVUE) to Report a Decline in Earnings: What to Look Out for
Kenvue (KVUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
Read More
All It Takes Is $1,000 Invested in Each of These 3 Dividend Kings to Help Generate Over $100 in Passive Income Per Year
Target, PepsiCo, and Kenvue have high yields and inexpensive valuations.
fool.com
Read More
Buy 7 October Dividend Kings, Watch 10 More
A Dividend King is a stock with 50 or more consecutive years of dividend increases per suredividend.com. The 53 Dividend Kings, screened as of October 8, represented 8 of 11 Morningstar Sectors. Broker-targeted top-ten net-gains ranged 13.99%-20.65% topped by Northwest Natural and United Bankshares. By yield, Altria tops all. Top-ten October dogs: HRL, KVUE, FRT, UBSI, FTS, BKH, NWN, CDUAF, UVV, and MO averaged 4.87% in yield.
seekingalpha.com
Read More
Buy 4 October Dividend Aristocrats & Watch 10
"Dividend Aristocrats... in the S&P500 Index… have raised their annual payouts every year for at least 25 consecutive years." -- Kiplinger.com/Investing. 67 Aristocrats, screened as of October 7, 2024 represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 10.5%-20.13% topped-by Franklin & Target.
seekingalpha.com
Read More
Kenvue: Turning Cautious On The Stock While Remaining Optimistic On The Business
Just like trying to catch falling knives, chasing stocks can be a dangerous endeavor. In this update, I share my latest thoughts on Kenvue stock, focusing specifically on the Q2 2024 results that sent the stock soaring 25%. I've incorporated the latest results into my valuation model and explain what the market is currently pricing in for KVUE stock.
seekingalpha.com
Read More
Kenvue Drives Climate Action Strategy Forward
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) is releasing its first Task Force on Climate-related Financial Disclosures (TCFD) report.
businesswire.com
Read More
Buy 7 September Dividend Kings, Watch 9 More
"What is a Dividend King? A stock with 50 or more consecutive years of dividend increases.” - suredividend.com. The 53 Dividend Kings, screened as of Sept. 10, represented eight of 11 Morningstar Sectors. Broker-targeted top 10 net gains ranged around 11.59%-35.94%, topped by Emerson and Stephan. By yield, Altria tops all. Top 10 September dogs: HRL, KVUE, FRT, FTS, UBSI, BKH, NWN, CDUAF, UVV, and MO averaged 4.70% in yield.
seekingalpha.com
Read More
Buy 4 September Dividend Aristocrats And Watch 6
The S&P 500 Dividend Aristocrats list was rebalanced in January 2024, with notable changes including the removal of Walgreens and 3M, and the addition of Fastenal and Kenvue.
seekingalpha.com
Read More
Kenvue Set To Pop Like A Tylenol Gelcap? Golden Cross Looms On Stock Chart
Kenvue Inc. KVUE — the parent company of well-known pharmacy items like Listerine, Mylanta, and Tylenol — is showing a bullish pattern on the charts Tuesday.
benzinga.com
Read More
5 Dividend Kings Provide Perfect Passive Income Streams for Retirement
24/7 Wall St. Insights Social Security is not enough to provide for a comfortable retirement.
247wallst.com
Read More
Worried About a Stock Market Sell-Off? Consider Coca-Cola, Pepsi, and These 3 Safe Dividend Kings for Decades of Passive Income.
Coca-Cola and Pepsi are two proven and reliable dividend stocks. Kenvue's high yield and established portfolio of consumer health brands make it a passive income powerhouse.
fool.com
Read More
Kenvue Announces Participation in the Barclays Global Consumer Staples Conference
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) (“Kenvue”) today announced the Company's participation in the Barclays Global Consumer Staples Conference in Boston, Massachusetts. Thibaut Mongon, Chief Executive Officer, Paul Ruh, Chief Financial Officer, and Charmaine England, Chief Growth Officer, will participate in a fireside chat on Thursday, September 5, 2024, at 3:00 p.m. Eastern Time. A live webcast of the session will be available on investors.kenvue.com and a replay will be.
businesswire.com
Read More
Passive Income Matters: These 3 Stocks Are Perennial Dividend Growers Worth Buying
Dividends represent the portion of a company's earnings paid to shareholders, typically on a quarterly basis.
247wallst.com
Read More
Lock in Gains: 3 Dividend Stocks Poised to Boost Payouts Soon
Investors looking for a respite from the ongoing market volatility may want to seek out dividend-paying stocks. The benefit of these stocks is that they give you an opportunity for reliable income today and into the future.
marketbeat.com
Read More
Kenvue Introduces Patented Micro-Peptide Technology with Neutrogena® Collagen Bank™ Launch
New Product Line Features Two Moisturizers Designed to Defend and Support the Skin's Natural Collagen SKILLMAN, N.J. , Aug. 15, 2024 /PRNewswire/ -- Kenvue Inc. (NYSE: KVUE) ("Kenvue" or the "Company"), the world's largest pure-play consumer health company by revenue, is launching Neutrogena®1 Collagen Bank™ featuring the Company's patented micro-peptide technology.
prnewswire.com
Read More
Buy These 5 Dividend Kings in August for Years of Passive Income
24/7 Wall St. Insights Passive income is among the best ways to supplement earnings from employment.
247wallst.com
Read More
7 Stable Dividend Stocks to Scoop Up on Discount
Following the severe market falloff that began last month but accelerated this month, investors may want to consider the inherent comfort of stable dividend stocks. No, these ideas aren't the most glamorous in the world – far from it.
investorplace.com
Read More
Kenvue: Promising Steps Toward Long-Term Success
Kenvue's share price recently spiked as a result of a strong second quarter earnings report. Kenvue's strong brands continued to gain market shares, showing progress despite challenges in the consumer environment. Strong brand performance with growth in well-known products like Listerine, Tylenol, Zyrtec, and Benadryl.
seekingalpha.com
Read More
Prediction: These 3 Dividend Stocks Will Pay More in Dividends in 2025
24/7 Wall St. Insights The bull market rally that started in the fall of 2023 may be coming to an end.
247wallst.com
Read More
53 August Dividend Kings: Buy 7, Watch 9 More
“What is a Dividend King? A stock with 50 or more consecutive years of dividend increases.”—suredividend.com. The 53 Dividend Kings, screened as of August 6, represented 8 of 11 Morningstar Sectors. Broker-targeted top-ten net-gains ranged 9.36%-31.67% topped-by PPG, and Target. By yield, Altria tops-all. Top-ten August dogs: NFG, FRT, KVUE, FTS, UBSI, BKH, NWN, CDUAF, UVV, & MO averaged 4.92% in yield.
seekingalpha.com
Read More
Kenvue Goes Boom - Now What?
Johnson & Johnson spun off its consumer segment into Kenvue, a $40 billion company in the consumer defensive sector. Kenvue operates in three main segments, including well-known brands like Tylenol, Neutrogena, and Listerine, with a global sales distribution. Despite recent underperformance, Kenvue saw a 14% stock price rally after reporting 2Q24 earnings, beating market expectations and showing signs of optimism.
seekingalpha.com
Read More
The 7 Best Under $20 Stocks to Buy in August 2024
Cheap stocks are often cheap for a reason. That bit of investing wisdom underscores the need to perform due diligence on a company and not just buy it because the stock trades at a low price.
investorplace.com
Read More
S&P 500 Gains and Losses Today: Kenvue Soars on Band-Aid Maker's Strong Outlook
Major U.S. equities indexes rebounded on Tuesday following three turbulent days of trading that saw heightened levels of economic uncertainty send stocks tumbling.
investopedia.com
Read More
Kenvue Inc. (KVUE) Q2 2024 Earnings Call Transcript
Kenvue Inc. (NYSE:KVUE ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Jim Giannakouros - Interim Head, Investor Relations Thibaut Mongon - Chief Executive Officer Paul Ruh - Chief Financial Officer Conference Call Participants Anna Lizzul - BofA Securities, Inc. Steve Powers - Deutsche Bank Securities, Inc. Andrea Teixeira - JPMorgan Securities LLC Nik Modi - RBC Capital Markets LLC Filippo Falorni - Citigroup Global Markets, Inc. Susan Anderson - Canaccord Genuity Jeremy Fialko - HSBC Peter Grom - UBS Operator Hello and welcome to the Kenvue Second Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise.
seekingalpha.com
Read More